Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

ANNX - Annexon Inc


IEX Last Trade
5.69
-0.240   -4.218%

Share volume: 614,339
Last Updated: Fri 30 Aug 2024 09:59:56 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology): 0.21%

PREVIOUS CLOSE
CHG
CHG%

$5.93
-0.24
-4.05%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
27%
Profitability 25%
Dept financing 20%
Liquidity 50%
Performance 25%
Company vs Stock growth
vs
Performance
5 Days
-3.23%
1 Month
-8.21%
3 Months
20.51%
6 Months
3.83%
1 Year
103.57%
2 Year
5.75%
Key data
Stock price
$5.69
P/E Ratio 
0.00
DAY RANGE
N/A - N/A
EPS 
$0.00
52 WEEK RANGE
$1.57 - $8.40
52 WEEK CHANGE
$0.96
MARKET CAP 
602.228 M
YIELD 
N/A
SHARES OUTSTANDING 
105.654 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/14/2024
BETA 
1.44
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$786,801
AVERAGE 30 VOLUME 
$954,514
Company detail
CEO:
Region: US
Website: annexonbio.com
Employees: 86
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

our mission is to develop disease-modifying therapeutics for patients suffering from neurological disorders such as huntington’s disease and alzheimer’s disease by targeting complement-mediated neurodegeneration (cmnd).

Recent news